Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

NCT01894061 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT01894061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01894061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2013
Completion date
July 1, 2019
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor